Protalix BioTherapeutics Announces Presentations at the 17th Annual WORLDSymposium(TM) 2021
CARMIEL, Israel, Feb. 1, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx(®) plant cell-based protein expression system, today announced that it will deliver an oral presentation and a poster presentation at the 17(th) Annual WORLDSymposium(TM), a research conference dedicated to lysosomal diseases being held virtually February 8-12, 2021. The oral and poster presentations will highlight data generated from the Company's BRIDGE Phase III 12 month open-label, single arm switch-over study evaluating the safety and efficacy of pegunigalsidase alfa.
Presentation Details:
Title: Switching from agalsidase alfa to pegunigalsidase alfa to treat patients with Fabry disease: 1 year of treatment data from BRIDGE, a phase 3 open-label study
Presenter: Ales Linhart, MD, Charles University, Praha, Czech Republic, a principal investigator in the Company's Phase III clinical trials of PRX-102 for the potential treatment of Fabry disease
Date/Time: The oral presentation is scheduled for Wednesday, February 10, 2021 at 1:24 PM EST
The poster presentation is scheduled for Wednesday, February 10, 2021 from 2:30 to 3:30 PM EST (Poster # 141)
Additional details can be found on the WORLDSymposium website at https://worldsymposia.org/. Copies of the presentation materials will be made available on the Company's website under the Presentations tab in the Investors section at the time of the poster session.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix was the first company to gain FDA approval of a protein produced through plant cell-based in suspension expression system. Protalix's unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.
Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.
Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified version of the recombinant human -Galactosidase-A protein for the proposed treatment of Fabry disease; OPRX-106, an orally-delivered anti-inflammatory treatment; alidornase alfa for the treatment of Cystic Fibrosis; and others. Protalix has partnered with Chiesi Global Rare Diseases, both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa.
Investor Contact
Chuck Padala, Managing Director
LifeSci Advisors
646-627-8390
chuck@lifesciadvisors.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/protalix-biotherapeutics-announces-presentations-at-the-17th-annual-worldsymposium-2021-301218819.html
SOURCE Protalix BioTherapeutics, Inc.
